Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Sponsor: Zhejiang Cancer Hospital
Summary
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of senaparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment。
Official title: Evaluation of Safety and Effectiveness of Senaparib in Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer: A Prospective Observational Real-World Study
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2026-06-10
Completion Date
2030-12-31
Last Updated
2026-05-14
Healthy Volunteers
No
Conditions
Interventions
Senaparib capsules(20mg)
senaparib monotherapy or combination therapy
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China